A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home Archive for category "AIMD Business" (Page 2)
formats

St. Jude’s Q1 2013 AIMD Results: CRM Down 7%, Neuromodulation Down 4%

St. Jude Medical announced sales results for Q1 2013.  AIMD results from their press release: “Cardiac Rhythm Management (CRM) Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $678 million for the first quarter of 2013, an 8 percent decrease compared to the first quarter of 2012. After adjusting for the

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude’s Q1 2013 AIMD Results: CRM Down 7%, Neuromodulation Down 4%  comments 
formats

Boston Scientific Releases 2012 AIMD Sales Report: CRM Down 7%, Neuromodulation Up 9%

Boston Scientific reported Q4 2012 CRM sales of $457M versus $482M for Q4 2011, or a decline of 5% (4% on constant-currency basis).  For the same period, neuromodulation sales grew by 14% from $91M to $104M. Worldwide CRM sales for the full 2012 year were $1,908M compared to $2,087M for 2011, or a decline of 9%

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific Releases 2012 AIMD Sales Report: CRM Down 7%, Neuromodulation Up 9%  comments 
formats

St. Jude Releases 2012 Year-End Results: CRM Down 6%, Neuromodulation Up 1%

St. Jude Medical today reported sales and net earnings for the fourth quarter and year ended December 29, 2012.   According to the announcement: “Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $682 million for the fourth quarter of 2012, a 6 percent decrease compared to the fourth quarter of 2011.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude Releases 2012 Year-End Results: CRM Down 6%, Neuromodulation Up 1%  comments 
formats

Boston Scientific Defibrillators Receive CE Mark for 10-Year Longevity Projections

  Boston Scientific has received CE Mark approval for increased longevity projections for the INCEPTA™, ENERGEN™, PUNCTUA™, COGNIS® and TELIGEN® implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The longevity projections are based on data submitted to the European authorities and vary for each device dependent on the model type and settings. Projected device

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific Defibrillators Receive CE Mark for 10-Year Longevity Projections  comments 
formats

Boston Scientific’s Q3 2012 AIMD Results: CRM Dropped 6%, Neuromodulation Up 5%

Today Boston Scientific reported its results for Q3 2012.  For its AIMD divisions: Cardiac Rhythm Management sales dropped from $503M in Q3 of 2011 to $462M for this year (-8%), a 6% decrease on constant-currency basis. Neuromodulation sales grew by 5% from $84M to $88M.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific’s Q3 2012 AIMD Results: CRM Dropped 6%, Neuromodulation Up 5%  comments 
formats

St. Jude’s Q3 2012 AIMD Results: CRM Maintains Downward Trend, Neuromodulation Steady

St. Jude announced today its third quarter 2012 results.  From the press release: “Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $691 million for the third quarter of 2012, an 8 percent decrease compared with the third quarter of 2011. Total CRM sales for the third quarter decreased 4 percent

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude’s Q3 2012 AIMD Results: CRM Maintains Downward Trend, Neuromodulation Steady  comments 
formats

EnteroMedics Reports $123k Revenue from Sales of its Maestro RC IPG for Treatment of Obesity

Today EnteroMedics recorded revenue for the first time since it was incorporated nearly eight years ago. The company reported revenue of about $123,000 in the first quarter of the year from the sale of its Maestro RC implantable vagus nerve stimulation system for treating obesity. Revenue was generated through sales by its distribution partner in Australia.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on EnteroMedics Reports $123k Revenue from Sales of its Maestro RC IPG for Treatment of Obesity  comments 
formats

Boston Scientific Q1 2012 AIMD Results: CRM Down 10%, Neuromodulation 8% Up

Yesterday Boston Scientific announced financial results for the first quarter ended March 31, 2012.  Sales of Cardiac Rhythm Management devices were $501M vs. $559M for Q1 a year ago, or a decrease of 10%.  Sales of  Neuromodulation devices increased by 8% a year ago from $77M to $84M for Q1.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific Q1 2012 AIMD Results: CRM Down 10%, Neuromodulation 8% Up  comments 
formats

St. Jude’s Reports Q1 2012 AIMD Sales Results: CRM down 4%, Neuromodulation up 12%

St. Jude Medical today reported sales and net earnings for the first quarter ended March 31, 2012. Total CRM sales, which include ICD and pacemaker products, were $735 million for the first quarter of 2012, a 4 percent decrease compared with the first quarter of 2011.  Of that total, ICD product sales were $450 million

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude’s Reports Q1 2012 AIMD Sales Results: CRM down 4%, Neuromodulation up 12%  comments 
formats

FDA AIMD PMA/Supplement Approvals for January

FDA released its PMA/Supplement approvals for January.   The edited version below has been edited to include only AIMDs.  It is not the full list, and should be used only for general information purposes.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on FDA AIMD PMA/Supplement Approvals for January  comments 
formats

Boston Scientific to Acquire Cameron Health for $150M Up-Front + $150M Upon FDA Approval

Boston Scientific announced the exercise of its option to acquire Cameron Health.  Cameron Health developed the world’s first and only commercially-available subcutaneous implantable cardioverter defibrillator – the S-ICD® System that I blogged about a few weeks ago. The agreement calls for an upfront payment of $150 million, payable upon transaction closing, an additional potential $150

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific to Acquire Cameron Health for $150M Up-Front + $150M Upon FDA Approval  comments 
formats

VeriTeQ Acquisition Corporation Acquires Implantable, FDA-Cleared VeriChip Technology

  On January 17, 2012, VeriTeQ Acquisition Corporation of Delray Beach, FL announced that it acquired the VeriChip implantable RFID technology and its related Health Link personal health record from PositiveID Corporation.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on VeriTeQ Acquisition Corporation Acquires Implantable, FDA-Cleared VeriChip Technology  comments 
formats

DF-4 Connectors for Implantable Cardioverter Defibrillators Enter Use in the US

The DF-4 Connector was recently introduced by a joint group of CRM companies, physicians, and regulatory agencies as a way of easing the implant of ICDs by reducing defibrillation connections from three to one and by minimizing the number of set screws.  Prior to the development of the DF-4, traditional high-voltage connector systems required up to three connections.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on DF-4 Connectors for Implantable Cardioverter Defibrillators Enter Use in the US  comments 
formats

Boston Scientific’s Active Implantable Sales for 2011: CRM Down 7%, Neuromodulation Up 10%

Today Boston Scientific Corporation announced financial results for the fourth quarter and full year ended December 31, 2011.  Summarizing the AIMD data: On a constant-currency basis, Q4 2011 CRM sales were $482M compared to $564M in Q4 2010, or  down 15% On a constant-currency basis, 2011 CRM sales were $2,087M compared to $2,180M in Q4 2010,

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific’s Active Implantable Sales for 2011: CRM Down 7%, Neuromodulation Up 10%  comments 
formats

St. Jude Medical’s Active Implantable Sales for 2011: CRM Down 3%, Neuromodulation Up 8%

St. Jude Medical today reported sales and net earnings for the fourth quarter and year ended December 31, 2011.    From the press release: “Cardiac Rhythm Management Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were$728 million for the fourth quarter of 2011, a 4 percent decrease compared to the fourth quarter of 2010.   After

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude Medical’s Active Implantable Sales for 2011: CRM Down 3%, Neuromodulation Up 8%  comments